Assenagon Asset Management
BPMC

Assenagon Asset Management’s Blueprint Medicines BPMC Stock Holding History

Assenagon Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-76,270
Closed -$6.75M – 1164
2025
Q1 		$6.75M Sell
76,270
-21,083
-22% -$2.06M 0.01% 487
2024
Q4 		$8.49M Sell
97,353
-3,280
-3% -$300K 0.01% 551
2024
Q3 		$9.31M Sell
100,633
-64,612
-39% -$6.42M 0.02% 553
2024
Q2 		$17.8M Sell
165,245
-9,864
-6% -$987K 0.04% 310
2024
Q1 		$16.6M Sell
175,109
-94,549
-35% -$8.11M 0.04% 318
2023
Q4 		$24.9M Buy
269,658
+260,321
+2,788% +$16.9M 0.07% 247
2023
Q3 		$469K Buy
+9,337
New +$499K ﹤0.01% 1207
2023
Q2 		– Sell
-49,847
Closed -$2.24M – 1344
2023
Q1 		$2.24M Buy
49,847
+13,636
+38% +$614K 0.01% 796
2022
Q4 		$1.59M Sell
36,211
-23,219
-39% -$1.11M 0.01% 896
2022
Q3 		$3.92M Sell
59,430
-399,376
-87% -$25.7M 0.02% 540
2022
Q2 		$23.2M Buy
458,806
+184,099
+67% +$10.8M 0.09% 205
2022
Q1 		$17.5M Buy
274,707
+216,374
+371% +$15.5M 0.05% 258
2021
Q4 		$6.25M Sell
58,333
-187,818
-76% -$19.6M 0.02% 451
2021
Q3 		$25.3M Sell
246,151
-16,108
-6% -$1.5M 0.08% 184
2021
Q2 		$23.1M Buy
+262,259
New +$24M 0.08% 208
2020
Q4 		– Sell
-86,281
Closed -$8M – 1032
2020
Q3 		$8M Buy
+86,281
New +$6.64M 0.04% 237
2020
Q2 		– Sell
-9,599
Closed -$561K – 1118
2020
Q1 		$561K Buy
9,599
+6,611
+221% +$425K ﹤0.01% 625
2019
Q4 		$239K Buy
+2,988
New +$224K ﹤0.01% 721
2019
Q2 		– Sell
-17,846
Closed -$1.43M – 1012
2019
Q1 		$1.43M Buy
+17,846
New +$1.32M 0.01% 600

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Assenagon Asset Management's BPMC Position: Q2 2025 in Review

Assenagon Asset Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 76,270 shares — an estimated $6.75M sold.

Assenagon Asset Management first reported a position in BPMC in Q1 2019 and held it in 19 quarters. The position peaked at $25.3M in Q3 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Assenagon Asset Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 76,270 Blueprint Medicines shares in Q2 2025, an estimated $6.75M.
  • Assenagon Asset Management first reported a position in Blueprint Medicines in Q1 2019 and held it in 19 quarters.
  • Assenagon Asset Management's Blueprint Medicines position peaked at $25.3M in Q3 2021.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Assenagon Asset Management's 13F filing for Q2 2025, filed 11 Jul 2025.